🇺🇸 FDA

Company profile · Sponsor

Lexeo

Lexeo Therapeutics

LXEO · NYSE biotech NEW YORK, NY, USA
Pipeline
3
Drugs
0
Patents
0

Quick answer

Lexeo (LXEO) is a biotech company. headquartered in NEW YORK, NY, USA. listed on NYSE. NovaPharmaNews links 3 pipeline programs, 0 drugs, and 0 patents to this profile..

Company facts

Ticker LXEO
Exchange NYSE
Company type biotech
Headquarters NEW YORK, NY, USA
SEC CIK 0001907108

Pipeline (3)

Search pipeline →

  1. LX2020

    Lexeo

    Arrhythmogenic Cardiomyopathy

    phase 2 gene therapy active

    1 trial

  2. Low dose LX2006

    Lexeo

    Friedreich Ataxia

    phase 2 gene therapy active

    1 trial

  3. LX1001

    Lexeo

    Alzheimer Disease

    phase 1 mab active

    1 trial

Frequently asked questions

What is Lexeo?

Lexeo (LXEO) is a biotech company. headquartered in NEW YORK, NY, USA. listed on NYSE. NovaPharmaNews links 3 pipeline programs, 0 drugs, and 0 patents to this profile..

What pipeline programs does Lexeo sponsor?

We track 3 ClinicalTrials.gov-linked programs for Lexeo, including LX2020 and 2 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Lexeo company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.